tirzepatide and wegovy F.D.A. Approves New Obesity Drug That Will Compete With Which Weight-Loss Drug Is Better:

By addressing both glucose regulation and appetite control, semaglutide targets the root causes of metabolic dysfunction rather than just the symptoms

These preclinical insights have been validated in large-scale clinical trials.The FLOW trial (n = 3,533) showed that once-weekly subcutaneous administration of semaglutide (1.0 mg) significantly reduced the risk of a renal composite endpointincluding 50% decline in eGFR, renal failure, or cardiovascular deathby 24% in patients with T2DM and chronic kidney disease (CKD) (HR = 0.76, 95% CI: 0.660.88

Seek medical help, improve the food choices you make, promote good sleeping patterns, and add strength training movement to your weekly routine

Joining Included Health allows us to bring that proven model to the biggest stage possible

Metabolic and alcohol-associated liver disease (MetALD): a representation of duality